Heparin does not improve myocardial glucose metabolism suppression in [18 F]FDG PET/CT in patients with low β-hydroxybutyrate level

Suvi Hartikainen,Ville Vepsäläinen,Tiina Laitinen,Marja Hedman,Tomi Laitinen,Tuomo Tompuri
DOI: https://doi.org/10.1186/s13550-024-01153-y
IF: 3.434
2024-10-10
EJNMMI Research
Abstract:Inadequate myocardial glucose metabolism suppression (GMS) can hamper interpretation of cardiac [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET/CT). Use of β-hydroxybutyrate (BHB) measurement before [ 18 F]FDG injection has been proposed for predicting adequate GMS. However, limited information is available on BHB measurement in guiding preparations for [ 18 F]FDG-PET/CT. The purpose of this study was t o evaluate if point-of-care measured BHB is useful in guiding heparin premedication for cardiac [ 18 F]FDG-PET/CT.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?